203 related articles for article (PubMed ID: 23943653)
1. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
[TBL] [Abstract][Full Text] [Related]
2. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.
Gopalakrishnan R; Matta H; Chaudhary PM
Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
[TBL] [Abstract][Full Text] [Related]
4. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
8. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
9. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
10. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
12. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
[TBL] [Abstract][Full Text] [Related]
13. Naughty chaperone as a target for viral cancer.
Ojala PM
Blood; 2013 Oct; 122(16):2767-8. PubMed ID: 24136075
[No Abstract] [Full Text] [Related]
14. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
15. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
16. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Marubayashi S; Koppikar P; Taldone T; Abdel-Wahab O; West N; Bhagwat N; Caldas-Lopes E; Ross KN; Gönen M; Gozman A; Ahn JH; Rodina A; Ouerfelli O; Yang G; Hedvat C; Bradner JE; Chiosis G; Levine RL
J Clin Invest; 2010 Oct; 120(10):3578-93. PubMed ID: 20852385
[TBL] [Abstract][Full Text] [Related]
17. KSHV vFLIP binds to IKK-gamma to activate IKK.
Field N; Low W; Daniels M; Howell S; Daviet L; Boshoff C; Collins M
J Cell Sci; 2003 Sep; 116(Pt 18):3721-8. PubMed ID: 12890756
[TBL] [Abstract][Full Text] [Related]
18. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
[TBL] [Abstract][Full Text] [Related]
19. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
20. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).
Liu M; Wang J; Wu X; Wang E; Baptista D; Scott B; Liu P
J Pharm Biomed Anal; 2014 Feb; 89():34-41. PubMed ID: 24252723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
